BIO-key Reports 33.5% Revenue Growth, 72% Reduction in Net Loss for Q1
Summary
BIO-key International reported strong Q1 2026 financial results, with revenue increasing 33.5% year-over-year to $2.15 million and net loss improving by 72.2% to ($205.04K). Diluted EPS also saw a significant improvement to ($0.2) from ($1.57) in the prior year. This operational improvement comes amidst severe challenges, including the company's recent Nasdaq delisting, a going concern warning, and a notice for late quarterly reporting.
At the time of this announcement, BKYI was trading at $3.90 on OTC in the Technology sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $3.10 to $19.70. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.